Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 99.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,833 shares of the specialty pharmaceutical company’s stock after selling 6,164,185 shares during the quarter. BNP Paribas Financial Markets’ holdings in Jazz Pharmaceuticals were worth $1,875,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the period. Arizona State Retirement System increased its stake in Jazz Pharmaceuticals by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. raised its holdings in Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock worth $1,004,000 after purchasing an additional 230 shares during the last quarter. Finally, Tectonic Advisors LLC boosted its position in Jazz Pharmaceuticals by 6.3% during the third quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company’s stock worth $433,000 after purchasing an additional 232 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,753 shares of company stock worth $816,289. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Trading Down 0.4 %

NASDAQ JAZZ opened at $122.59 on Friday. The company has a 50-day moving average of $116.18 and a 200-day moving average of $111.59. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a market cap of $7.41 billion, a P/E ratio of 17.27, a P/E/G ratio of 1.04 and a beta of 0.57.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Finally, Piper Sandler reissued an “overweight” rating and set a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Get Our Latest Report on JAZZ

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Read More

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.